^
Association details:
| Biomarker: | PIK3CA H1047R |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Excerpt:
Patients with HR-positive breast cancer who were treated with everolimus...In total, 120 patients with metastatic breast cancer who were treated with everolimus...Patients with the PIK3CA/H1047R mutation had longer PFS than patients with wild-type or other mutant forms of PIK3CA, and the median PFS in these two groups of patients was 8.8 and 4.1 months, respectively (p < 0.05).
DOI:
10.1186/s12885-019-5668-3
